Abstract
HLA genes play a pivotal role in an immune response via the presentation of pathogen peptides in a complex on the surface of cells of a host organism. Here, we studied the association of class I and class II genes with the severity of COVID-19 infection and HLA allele variants.
We performed high-resolution sequencing of class I and class II HLA genes using the sample population of 147 patients who died of COVID-19 and statistically compared our results with the frequencies of the HLA genotypes in a control population of 270 samples.
The obtained data demonstrated that 51:05 and 15:18 alleles from locus B* are statistically significantly associated with COVID-19 severity, while C*14:02 allele correlates with the probability of death from COVID-19 for patients without comorbidities.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by grant №075-15-2019-1789 from the Ministry of Science and Higher Education of the Russian Federation allocated to the Center for Precision Genome Editing and Genetic Technologies for Biomedicine.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study conformed to the principles of the Declaration of Helsinki. The appropriate institutional review board approval for this study was obtained from the Ethics Committee at Pirogov Medical University. All patients provided written informed consent for the collection of samples, subsequent analysis, and publication thereof.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All received data are available upon request
